In brief: Psivida, Eqitx, Ellex, BRC, AFT
Tuesday, 26 July, 2005
Following its recent Nasdaq listing, Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has appointed the president and CEO of New Jersey-based Chugai Pharma USA, David J Mazzo, as a non-executive director.
Eqitx (ASX:EQX) has lost two of its Perth-based directors, Brian Nathanson and Geoff Harland, following the company's relocation to Melbourne earlier this year.
David Lindh has retired as Ellex Medical's (ASX:ELX) chairman to focus on his role as chairman of Adelaide-based Rundle Capital Partners. He is replaced by Victor Previn. Alex Sundich, CFO of Record Investments (ASX:RCD), has been appointed to the board.
The Brain Resource Company (ASX:BRC) has raised AUD$1.6 million in a private placement of 5.9 million ordinary shares representing 7.5 per cent of the company's existing share capital. It has also appointed Bivest Group CEO Brian Joffe as a non-executive director. A private entity associated with Joffe subscribed to around half of the placement.
AFT Corp (ASX:AFT) has completed the acquisition of Microgenix System and now owns 100 per cent of its air purification technology. Philip Hall has resigned as a director of AFT and Microgenix, although he will remain as a consultant to AFT. The company has issued just over 44 million shares and 2 million convertible notes at a face value of $1 each to TechSuccess, a company associated with Hall.
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
Vaccine for elephant herpesvirus found to be safe
The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...
